Monokine induced by gamma interferon as a marker of systemic hydroa vaccniforme lymphoproliferative disorder - 03/12/24
Doi : 10.1016/j.jaad.2024.10.068
Tomoko Miyake, MD, PhD a, ⁎ 
, Takenobu Yamamoto, MD, PhD b, Yoji Hirai, MD, PhD a, Takahide Takahashi, MD c, Takuya Furuhashi, MD, PhD d, Hisashi Nomura, MD, PhD e, Yoshio Kawakami, MD, PhD a, Shin Morizane, MD, PhD a
, Takenobu Yamamoto, MD, PhD b, Yoji Hirai, MD, PhD a, Takahide Takahashi, MD c, Takuya Furuhashi, MD, PhD d, Hisashi Nomura, MD, PhD e, Yoshio Kawakami, MD, PhD a, Shin Morizane, MD, PhD a a Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
b Department of Dermatology, Kawasaki Medical School, Okayama, Japan
c Division of Medical Support, Okayama University Hospital, Okayama, Japan
d Department of Dermatology, Kasugai Municipal Hospital, Aichi, Japan
e Department of Dermatology, Shizuoka City Shimizu Hospital, Shizuoka, Japan
∗Correspondence to: Tomoko Miyake, MD, PhD, Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, JapanDepartment of DermatologyOkayama University Graduate School of MedicineDentistry and Pharmaceutical Sciences2-5-1 Shikata-choKita-kuOkayama700-8558Japan
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Tuesday 03 December 2024
Key words : classical HV, Epstein-Barr virus, hydroa vaccniforme lymphoproliferative disorder, monokine induced by gamma interferon, systemic HV
| Funding sources: Supported by a grant from Grant-in-Aid for Early-Carrer Scientists (18K16063, 20K17352), Japan; GSK grand (B-47), Japan, Daiichi Sankyo company (A20-1038), Japan, and Novartis Research Grants 2019, Japan. |
|
| Patient consent: Consent for the publication of recognizable patient photographs or other identifiable material was obtained by the authors and included at the time of article submission to the journal stating that all patients gave consent with the understanding that this information may be publicly available. |
|
| IRB approval status: Approval was obtained from Okayama University Hospital (no. 1610-008). |
© 2024
American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?